Limited Offer
Osteoporosis
- 3rd Edition - November 8, 2007
- Editors: Robert Marcus, David Feldman, Dorothy Nelson, Clifford Rosen
- Language: English
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 5 5 3 4 7 - 4
Now in its third edition, Osteoporosis, is the most comprehensive, authoritative reference on this disease. Written by renowned experts in the field, this two-volume refere… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNow in its third edition, Osteoporosis, is the most comprehensive, authoritative reference on this disease. Written by renowned experts in the field, this two-volume reference is a must-have for academic and medical libraries, physicians, researchers, and any company involved in osteoporosis research and development. Worldwide, 200 million women between 60-80 suffer from osteoporosis and have a lifetime risk of fracture between 30 and 40 percent continuing to make osteoporosis a hot topic in medicine. This newest edition covers everything from basic anatomy and physiology to diagnosis, management and treatment in a field where direct care costs for osteoporitic fractures in the U.S. reach up to $18 billion each year.
NEW TO THIS EDITION:
*Recognizes the critical importance of the Wnt signaling pathway for bone health
*Incorporates new chapters on osteocytes, phosphatonins, mouse genetics, and CNS and bone
*Examines essential updates on estrogen prevention and treatment and the recent results from the WHI
*Discusses the controversial topics of screening and clinical trial design for drug registration
*Includes essential updates on therapeutic uses of calcium, vitamin D, SERMS, bisphosphonates, and parathyroid hormone
* Offers critical reviews of reproductive and hormonal risk factors, ethnicity, nutrition, therapeutics, management, and economics comprising a tremendous wealth of knowledge in a single source not found elsewhere
*Recognizes the critical importance of the Wnt signaling pathway for bone health
*Incorporates new chapters on osteocytes, phosphatonins, mouse genetics, and CNS and bone
*Examines essential updates on estrogen prevention and treatment and the recent results from the WHI
*Discusses the controversial topics of screening and clinical trial design for drug registration
*Includes essential updates on therapeutic uses of calcium, vitamin D, SERMS, bisphosphonates, and parathyroid hormone
* Offers critical reviews of reproductive and hormonal risk factors, ethnicity, nutrition, therapeutics, management, and economics comprising a tremendous wealth of knowledge in a single source not found elsewhere
Academic and medical libraries as well as professionals in bone biology, endocrinology, osteology, neuroendocrinology; drug companies developing osteoporosis medications
- No. of pages: 2016
- Language: English
- Edition: 3
- Published: November 8, 2007
- Imprint: Academic Press
- eBook ISBN: 9780080553474
RM
Robert Marcus
Dr. Marcus is Professor-Emeritus, Stanford University, where he served on the full-time medical faculty for almost 25 years, before joining the Emeritus faculty in 2001. At Stanford, he was located at the Veterans Affairs Medical Center, Palo Alto California, where he served as Director of the Aging Study Unit of the Geriatrics Research, Education, & Clinical Center from 1982-2001. Dr. Marcus enjoyed a long career as a clinical investigator in the fields of bone and mineral metabolism and osteoporosis medicine. His own research interests included diagnosis and therapy of primary hyperpara-thyroidism, interactions of the parathyroid-vitamin D axis with estrogen, age-related changes in the growth hormone-IGF axis, effects of growth hormone replacement for older men and women, metabolic and musculoskeletal effects of resistance exercise in older men and women, adolescent bone acquisition, and osteoporosis therapeutics. Dr. Marcus’ laboratory was a study site for many of the pivotal clinical trials in the osteoporosis field. These include the NIH Post-menopausal Estrogen/Progestin Interventions Trial (PEPI), Merck’s Fracture Intervention Trial (FIT), Lilly’s Multiple Outcomes of Raloxifene Intervention (MORE), and Lilly’s registration trial of recombinant PTH(1-34) in the treatment of postmenopausal women with osteoporosis. In 2001. Dr. Marcus joined the US Affiliate of Eli Lilly & Company to support Lilly’s program in Osteoporosis and Skeletal Medicine. From 2003 until his retirement from Lilly in 2008, Dr. Marcus was the lead physician for the Forteo team at Lilly. He has published more than 150 research papers, editorials, and reviews. Dr. Marcus served as President of the American Society for Bone & Mineral Research in 2000-2001.
Affiliations and expertise
Professor Emeritus, Department of Medicine, Stanford University School of Medicine, CA, USADF
David Feldman
Affiliations and expertise
Stanford University School of Medicine, Stanford, California, USADN
Dorothy Nelson
Affiliations and expertise
Wayne State University, Detroit, MI, U.S.A.CR
Clifford Rosen
Dr. Rosen is Professor and Senior Scientists at The Jackson Laboratory, Bar Harbor, Maine, where his group studies the role of insulin-like growth factors on bone and the genetics of osteoporosis in inbred strains of mice. In 2007 he joined the Maine Medical Center Research Institute in Scarborough, Maine. He is also the former Director of the Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, Bangor.
Dr. Rosen is a Past President of the American Society of Bone and Mineral Research (ASBMR). He served five years as the First Editor in Chief of the Journal of Clinical Densitometry, the official journal for the International Society of Clinical Densitometry, and currently serves as Associate Editor of the Journal of Bone and Mineral Research. His publications exceed 270 manuscripts published in a wide spectrum of clinical and basic science journals.
Affiliations and expertise
Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, Bangor, Maine, USA